Aug 19, 2025, 08:29

CurePSP Pathway & Pipeline Grants

Seed funding for innovative PSP/CBD research that needs pilot/proof-of-concept data. Two tracks: Pathway (fundamental disease mechanisms) and Pipeline (translational biomarkers and therapeutics). Up to USD 100,000 for 1–2 years.

Eligibility Criteria:

Open to international academic and research-conducting nonprofits (not in U.S.-sanctioned countries).
PI must hold an advanced degree (e.g., MD, PhD, DO, DVM, ScD); early-career and postdoctoral/medical fellows are eligible.
Projects must focus on PSP/CBD; other tauopathies/proteinopathies require a strong cross-disease rationale.

Funding Details:

Up to USD 100,000 total for 1–2 years; direct costs only (no indirects).
Allowable: personnel, supplies/consumables, publication/data-sharing costs, permanent equipment (typically ≤ USD 8,000), and limited travel (e.g., CurePSP research symposium).
Budget flexibility for minor changes; major scope/timeline changes require prior approval.

Deadline:

Submission due: October 3, 2024 (5:00 p.m. ET).
Notifications by February 2025; earliest start March 1, 2025. (Refer to the program page for the next cycle.)

Where to Go for Further Information:

Submit via ProposalCentral search “CurePSP Pathway and Pipeline Grant.”
Program contact: Dr. Jennifer Brummet — [email protected].

biomarkers corticobasal degeneration CurePSP neurodegeneration no indirect costs OncoDaily Pathway grant Pipeline grant progressive supranuclear palsy proposalCENTRAL seed funding tauopathy translational research

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth